Artisan Partners Limited Partnership Purchases 75,830 Shares of Celcuity Inc. (NASDAQ:CELC)

Artisan Partners Limited Partnership boosted its position in shares of Celcuity Inc. (NASDAQ:CELC) by 18.2% during the 4th quarter, HoldingsChannel reports. The firm owned 491,507 shares of the company’s stock after buying an additional 75,830 shares during the period. Artisan Partners Limited Partnership’s holdings in Celcuity were worth $6,434,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. BNP Paribas Financial Markets increased its stake in shares of Celcuity by 2,083.4% during the third quarter. BNP Paribas Financial Markets now owns 45,110 shares of the company’s stock valued at $673,000 after buying an additional 43,044 shares during the period. Geode Capital Management LLC grew its holdings in Celcuity by 27.6% during the 3rd quarter. Geode Capital Management LLC now owns 630,369 shares of the company’s stock worth $9,401,000 after acquiring an additional 136,518 shares in the last quarter. State Street Corp increased its position in Celcuity by 152.2% during the 3rd quarter. State Street Corp now owns 1,107,415 shares of the company’s stock valued at $16,512,000 after purchasing an additional 668,318 shares during the period. Braidwell LP raised its holdings in shares of Celcuity by 71.2% in the 3rd quarter. Braidwell LP now owns 884,306 shares of the company’s stock valued at $13,185,000 after purchasing an additional 367,663 shares in the last quarter. Finally, Barclays PLC lifted its position in shares of Celcuity by 567.6% in the 3rd quarter. Barclays PLC now owns 53,605 shares of the company’s stock worth $800,000 after purchasing an additional 45,576 shares during the period. 63.33% of the stock is owned by institutional investors.

Celcuity Trading Down 2.8 %

NASDAQ CELC opened at $10.24 on Friday. Celcuity Inc. has a 52 week low of $8.53 and a 52 week high of $22.04. The company has a 50 day moving average price of $11.20 and a 200 day moving average price of $12.98. The company has a quick ratio of 10.36, a current ratio of 10.35 and a debt-to-equity ratio of 0.65. The firm has a market cap of $380.21 million, a PE ratio of -3.92 and a beta of 0.65.

Analyst Ratings Changes

Separately, Needham & Company LLC boosted their price objective on shares of Celcuity from $23.00 to $29.00 and gave the stock a “buy” rating in a research note on Thursday, February 6th. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Celcuity presently has a consensus rating of “Buy” and a consensus target price of $30.17.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.